Australia markets closed

  • ALL ORDS

    7,009.90
    -32.80 (-0.47%)
     

  • AUD/USD

    0.7799
    +0.0022 (+0.29%)
     

  • ASX 200

    6,762.30
    -27.30 (-0.40%)
     

  • OIL

    60.66
    +0.02 (+0.03%)
     

  • GOLD

    1,727.50
    +4.50 (+0.26%)
     

  • BTC-AUD

    62,678.14
    +1,175.22 (+1.91%)
     

  • CMC Crypto 200

    984.19
    -2.46 (-0.25%)
     
✉️ Free sign-up:

Get the news straight to your inbox every day.

Stay in the loop every day with Yahoo Finance's free Fully Briefed newsletter.

Global Carbon Neutral Data Center Market (2020 to 2025) - Impact Analysis of COVID-19 - ResearchAndMarkets.com

·4-min read

The "Carbon Neutral Data Center Market - A Global and Regional Analysis: Focus on Carbon Neutral Data Center Types & Solutions, End-Use Industry, Government Programs, Trends, Opportunities and Country Analysis" report has been added to ResearchAndMarkets.com's offering.

The carbon neutral data center market is projected to grow from $3.46 billion in 2020 to $9.42 billion by 2025, at a CAGR of 22.17% from 2020 to 2025.

The growth in the carbon neutral data center market is expected to be driven by various government policies and environmental regulations especially which are aligned to reducing carbon emissions, for example, the International Climate Agreement. Apart from this, the ongoing trend of Industry 4.0 and digital transformation, which has increased the amount of data being produced due to the data intensive nature of the applications, has significantly impacted the market.

The carbon neutral data center market by industry has the largest share in the IT and telecom industry, followed by the BFSI industry. The IT and telecom industry or the ICT industry is a data-driven industry. Almost all the applications are data intensive and generate a huge amount of data in the entire value chain. The telecom industry is dependent upon data centers as data transmission during internet services requires constant storage and processing, which is a primary criterion for quality services. Thus, in order to maintain quality, the industry has to rely on data center facilities.

The hyperscale data centers have the highest potential in the carbon neutral data center market by data center type. It is expected to be the most impacted type as most of the hyperscale operators and service providers such as Google and Microsoft have pledged to achieve carbon neutrality in their entire value chain by 2030. The companies have shown that lower PUE levels are possible to achieve with the use of efficient technologies utilizing renewable energy in the entirety of data center operations.

Apart from this, the ongoing trend of cloud migration has also helped the market for hyperscale data center types. The colocation type data center is accounted for the second-largest share in the market. The ongoing trend of digitization and the development of various technologies such as extended reality, internet of things (IoT), artificial intelligence (AI), and other enabling technologies have helped many start-ups to grow. These start-ups do not have much financial support to own and operate a data center that supports their operations. This is where the colocation data centers become a solution for the needs of various smaller organizations with data center demands.

Impact of COVID-19 on Carbon Neutral Data Center Market

COVID-19 has restricted the growth of almost every industry globally owing to the measures such as lockdown and travel restrictions undertaken by the governments. Due to this, the entire supply chain of the data center industry has been negatively affected. This has restricted the flow of various equipment and devices, which are essential for data center operations, due to which many data centers were not able to get commissioned, and many projects were stalled. The lockdown also restricted people from traveling, which disallowed many data center architects and engineers to reach onsite for the construction of new facilities and maintenance of existing facilities.

The server utilization rate was also affected due to the halt in various computing activities in almost every industry. Many operators have reported that almost half of the servers were online during the pandemic. However, industries such as telecom, which is the largest consumer of data center, operated in their fullest capacity and thus maintained the demand for data transmission and transfer services. This has also helped the industry to maintain a minimum operational return from the online services.

Market Dynamics

Drivers

  • Government Regulations on Carbon Emissions and Rising Emphasis on Renewable Energy

  • Growing Energy Efficient Alternatives for Data Center Cooling

  • Sustainable Development Efforts and CSR Activities

  • Rising Electricity Tariffs Globally

Restraints

  • High Dependence on Non-Renewable Energy for Running Data Center Operations

  • Higher Costs of Implementation and Compatibility Issues

Opportunities

  • Increasing Research and Development in Energy Storage Technologies

  • Increased Demand for Data Centers and Mega Data Centers

  • Transition from Onsite Storage Facility Toward Cloud Connectivity

Companies Mentioned

  • 3M Company

  • ABB Group

  • Alibaba Group

  • Alphabet Inc.

  • Amazon.com, Inc.

  • Cisco Systems, Inc.

  • Dell Inc.

  • Digital Realty Trust, Inc.

  • Eaton Corporation plc

  • Equinix

  • Fujitsu Ltd

  • Hewlett Packard Enterprise (HPE)

  • IBM Corporation

  • Intel Corporation

  • Microsoft Corporation

For more information about this report visit https://www.researchandmarkets.com/r/dj94qq

View source version on businesswire.com: https://www.businesswire.com/news/home/20210127005597/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Latest stories

  • Ghana kicks off coronavirus vaccination campaign with COVAX shots

    Ghana began its coronavirus vaccination drive on Tuesday with 600,000 AstraZeneca doses it received from the global COVAX vaccine-sharing facility aimed at providing shots to developing nations to help combat the COVID-19 pandemic. People lined up for shots outside the regional hospital in the capital, Accra, for a first phase of vaccinations which will prioritise frontline health workers and others at high risk. While western nations have secured millions of doses and launched mass vaccination drives, most poorer countries do not yet have access to any, raising concerns about equitable distribution of vaccines to fight the pandemic.

  • Stone Gold signs drill contract for Mt. Jamie North Property in Red Lake, Ontario

    Mt. Jamie North Gold Project Geology and Highlights TORONTO, March 02, 2021 (GLOBE NEWSWIRE) -- Stone Gold Inc. (TSX-V: STG) ("Stone Gold" or the "Company") is pleased to announce that it has signed a diamond drilling contract with Rodren Drilling Ltd. for the Mt. Jamie North property located in Red Lake, Ontario. The preliminary drill program is for a minimum of 900 metres NQ drilling and is expected to be completed by end of March 2021. Stone Gold President and CEO John Timmons states, “We are excited to have the opportunity to drill the untested Mt. Jamie North Property located in Red Lake. All the targets for this program are on strike with the historical Mt. Jamie Mine and West Red Lakes Rowan Mine Property that has 1.1 million inferred ounces of gold. We hope to further the evidence of gold mineralization along the western trend of the Red Lake mining camp.” To view the accompanying “Mt. Jamie North Gold Project – Geology and Highlights” photo, please visit:https://www.globenewswire.com/NewsRoom/AttachmentNg/f0c49b52-bcfa-4ca1-9d1b-9a1eb0dcc536 For further information, please contact:Mr. John TimmonsPresident & CEOStone Gold Inc.Cellular (416) 931 2243Email: jtimmons@stonegold.caWeb: www.stonegold.ca Stone Gold Inc. is engaged in the acquisition, exploration and evaluation of properties for the mining of precious and base metals. Caution Regarding Forward-Looking Information This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Stone Gold. Forward-looking statements include estimates and statements that describe Stone Gold's future plans, objectives or goals, including words to the effect that Stone Gold or its management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as "believes", "anticipates", "expects", "estimates", "may", "could", "would", "will", or "plan". Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to Stone Gold, Stone Gold provides no assurance that actual results will meet management's expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to, Stone Gold's objectives, goals or future plans, statements, details of the exploration results, potential mineralization, Stone Gold's portfolio, treasury, management team and enhanced capital markets profile, the timing of the Transaction, the estimation of mineral resources, exploration and mine development plans, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, failure or inability to complete the Transaction on the terms as announced or at all, regulatory approval processes, failure to identify mineral resources, delays in obtaining or failures to obtain required governmental, regulatory, environmental or other project approvals, political risks, inability to fulfill the duty to accommodate First Nations and other indigenous peoples, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects, capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry, and those risks set out in Stone Gold's public documents filed on SEDAR. Although Stone Gold believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Stone Gold disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.

  • Unifrax, Backed by Clearlake Capital, Announces Lithium Ion Battery Anode Technology Coming Early Next Year

    Unifrax, the leading manufacturer of high-performance specialty materials, today introduced its latest proprietary technology, SiFAB™ Silicon Fiber Anode Battery Technology by Unifrax. SiFAB, currently in advanced testing after years of research and development, has shown promising performance in multiple battery systems. This anode technology enables significantly higher energy density in lithium ion battery systems and has successfully been tested with incremental Si loadings of greater than 40 percent.

  • Post-Covid consumer boom to hit US high streets

    A consumer boom looks set to hit US high streets as "pent-up" spending is released into the economy. Questionmark, the online assessment provider, is calling on employers to ensure they have the staff they need, with the right skills, to take advantage of the post-Covid splurge.

  • OLB Group Simplifies Social Media App Payment Acceptance for Merchants

    The OLB Group, Inc. (NASDAQ: OLB), a provider of cloud-based omnicommerce and payment acceptance solutions for small and mid-size merchants, announced its SecurePay payment gateway now provides merchants of every size with seamless payment acceptance through popular social media platforms and lifestyle apps. SecurePay’s direct integration at the payment gateway assures efficient and secure payment processing for customers wishing to make purchases without leaving a favorite app.

  • Titan Medical to Present at H.C. Wainwright Global Life Sciences Conference

    Titan Medical Inc. ("Titan" or the "Company") (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced that David McNally, President, CEO and Chairman of Titan Medical, will present an overview of the Company and its Enos™ robotic single access surgical system at the H.C. Wainwright virtual Global Life Sciences Conference on Tuesday, March 9, 2021 at 7:00 a.m. ET. A link to the presentation will be available for on-demand access beginning Tuesday, March 9, 2021, on Titan Medical’s website under the "Investors" section.

  • Verastem Oncology to Participate in the H.C. Wainwright Global Life Sciences Conference

    Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will participate in the virtual H.C. Wainwright Global Life Sciences Conference. The fireside chat will be made available for on-demand listening beginning Tuesday, March 9, 2021 at 7:00 a.m. EST.

  • Glaukos Announces Participation in Oppenheimer Healthcare Conference

    Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the Oppenheimer 31st Annual Healthcare Conference on Tuesday, March 16, 2021, at 3:10 p.m. EDT.

  • ALX Oncology to Participate at H.C. Wainwright Global Life Sciences Conference

    BURLINGAME, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in a fireside chat at H.C. Wainwright’s Global Life Sciences Conference, being held virtually on March 9-10, 2021. The prerecorded fireside chat will be available on Tuesday, March 9, 2021 at 7:00 a.m. Eastern Time here and can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com and selecting Events under the News and Events tab. A replay of the webcast will be archived for up to 30 days following the presentation date. About ALX Oncology ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. ALX148 has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of ALX148 for the treatment of a range of solid tumor indications as well as MDS and AML. For more information, please visit ALX Oncology’s website at www.alxoncology.com. CONTACT: Investor Contact: Peter Garcia Chief Financial Officer, ALX Oncology (650) 466-7125 Ext. 113 peter@alxoncology.com Argot Partners (212) 600-1902 alxoncology@argotpartners.com Media Contact: Karen Sharma MacDougall (781) 235-3060 alx@macbiocom.com

  • AGTC to Present at Upcoming Investor Conferences

    GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that management will be participating in the following virtual investor conferences: H.C. Wainwright Global Life Sciences Conference ‎(March 9-10, 2021)A fireside chat with Sue Washer, President & Chief Executive Officer, will be available to view on-demand beginning Tuesday, March 9, 2021 at 7:00 a.m. ET through the entirety of the conference. 33rd Annual ROTH Conference (March 15-17, 2021)Ms. Washer and Mark Shearman, Chief Scientific Officer, will participate in a fireside chat at 1:00 p.m. ET on Monday, March 15, 2021. Audio webcasts of the presentation at the H.C. Wainwright and ROTH conferences can be accessed by visiting http://ir.agtc.com/events-and-presentations. A replay will be available on the Company's website following the events. About AGTCAGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company’s industry-leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. IR/PR CONTACTS: David Carey (IR) or Glenn Silver (PR)Lazar FINN PartnersT: (212) 867-1768 or (646) 871-8485david.carey@finnpartners.com or glenn.silver@finnpartners.com Corporate Contacts:Bill SullivanChief Financial OfficerApplied Genetic Technologies CorporationT: (617) 843-5728 bsullivan@agtc.com Stephen PotterChief Business OfficerApplied Genetic Technologies CorporationT: (617) 413-2754spotter@agtc.com

  • Chimerix to Present at Virtual H.C. Wainwright Global Life Sciences Conference

    DURHAM, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright Global Life Sciences Conference made available on Tuesday, March 9, 2021 at 7:00 a.m. ET. An audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days. About Chimerix Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. Our three most advanced clinical-stage development programs are BCV, ONC201 and DSTAT. BCV is an antiviral drug candidate developed as a potential medical countermeasure for smallpox and is currently under review for regulatory approval in the United States. ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and a confirmatory response rate assessment is expected later this year. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia and as a potential treatment for acute lung injury in hospitalized COVID-19 patients. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, Chimerix’s ability to obtain regulatory approval for BCV; the timing and receipt of a potential procurement contract for BCV in smallpox; and the timing of enrollment in the DSTAT trial for AML. Among the factors and risks that could cause actual results to differ materially from those indicated in the forward-looking statements are risks that BCV may not obtain regulatory approval from the FDA or such approval may be delayed or conditioned; risks that Chimerix will not obtain a procurement contract for BCV in smallpox in a timely manner or at all; risks related to the timing and conduct of the DSTAT trials for AML and COVID; risks that ongoing or future trials may not be successful or replicate previous trial results, or may not be predictive of real-world results or of results in subsequent trials; risks and uncertainties relating to competitive products and technological changes that may limit demand for our drugs; risks that our drugs may be precluded from commercialization by the proprietary rights of third parties; and additional risks set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. CONTACT:Investor Relations: Michelle LaSpaluto919 972-7115ir@chimerix.comWill O’ConnorStern Investor Relations212-362-1200will@sternir.com

  • GTreasury Acquires Coprocess, the Leader in Intercompany Netting Solutions

    Deal gives GTreasury fully-integrated netting technology to meet growing customer demand for global netting and reconciliation capabilitiesCHICAGO, March 02, 2021 (GLOBE NEWSWIRE) -- GTreasury, a treasury and risk management platform provider, today announced the acquisition of Coprocess, the leading provider of intercompany netting solutions. Adding intercompany netting to the GTreasury platform and ecosystem gives corporate treasurers the ability to significantly streamline their settlement processes, cut costs by reducing payments and FX volumes, and add new automated efficiencies into their treasury workflows. “GTreasury continues to look for ways to empower corporate treasurers to do their jobs more effectively, more efficiently, and with less cost to their organizations,” said Renaat Ver Eecke, CEO, GTreasury. “The complexities of doing business across countries and across banks continues to grow, and the technologies that treasurers rely on must keep up with that pace. Acquiring Coprocess does exactly that for our clients. Coprocess brings expertise in multilateral netting that is second to none, and we’re extremely excited to welcome the Coprocess team, learn from them, and jointly build new and fully integrated solutions that will directly benefit our customer base.” Treasurers using Coprocess regularly see payments and FX volumes lowered by as much as 70%, while also benefiting from more centralized banking relationships and reduced float and complexity. Real-time intercompany reconciliation capabilities deliver visibility into intercompany transactions, interest, loans and treasury transactions – eliminating mismatches and facilitating automatic reporting. Fully centralized vendor payments further simplify often-costly and time-intensive treasury operations. The Coprocess solution is also highly configurable to businesses’ unique netting processes and organizational structures, and easily incorporates into treasurers’ existing architectures. Combining the leading netting system with GTreasury’s extensive cash, payments, FX, and risk management capabilities provides treasurers with an extensive, easy-to-use, and end-to-end solution for optimizing their treasury processes and workflows. The acquisition also continues to build the momentum of the GTreasury platform. “We saw record transaction volume flow though our treasury management ecosystem in 2020,” said Ver Eecke. “To continue to meet our clients’ needs, we’ve been signing key partnerships with banks and complementary technology providers, expanded our platform through new innovations like SmartPredictions™, our AI-fueled cash forecasting, and executed on strategic acquisitions such as with Visual Risk and now Coprocess.” Founded in 1991, Coprocess has established itself as the leading intercompany netting provider. The company’s 175 global clients across a range of industries leverage the Coprocess solution to net millions of invoices per year and save hundreds of thousands of dollars in FX and transaction expenses. “Like Coprocess, GTreasury has long been a trusted technology partner to organizations around the world,” said Andrew Goldie, CEO, Coprocess. “They understand that continual innovation is critical to ensuring treasurers can do their jobs faster, with more accurate foresight, and as cost-efficiently to their businesses as possible. We share these aims, and look forward to a great future for Coprocess within GTreasury. We are excited to put our comprehensive netting solution into the hands of more treasurers.” About GTreasury For more than 30 years, GTreasury has delivered the leading digital Treasury and Risk Management System (TRMS) to corporate treasurers across industries. With its continually innovating Software-as-a-Service platform, GTreasury provides customers with a single source of truth for all their cash, payments, and risk activities. The TRMS solution offers any combination of Cash Management, Payments, Financial Instruments, Risk Management, Accounting, Banking, and Hedge Accounting – seamlessly integrated, on-demand worldwide and fully secured. Headquartered in Chicago with offices serving EMEA (London) and APAC (Sydney and Manila), GTreasury’s global community includes more than 800 customers and 30+ industries reaching 160+ countries worldwide. ContactBret Clementbret@clementpeterson.com

  • IN8bio Presents Gamma-Delta T Cells as Cancer Therapeutics at the ESMO Targeted Anticancer Therapies Virtual Conference 2021

    NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (“IN8bio” or the “Company”), a clinical-stage biotechnology company focused on developing innovative gamma-delta T cell therapies, announced a presentation on the scientific rationale and clinical basis for the use of gamma-delta T cells and the company’s Drug Resistant Immunotherapy (DRI) approach to target solid tumor cancers. The oral presentation, entitled “Gamma-Delta T Cell Therapeutics for Treatment of Solid Tumors,” was delivered at the European Society for Medical Oncology (ESMO) Targeted Anticancer Therapies virtual conference on March 1, 2021 by IN8bio’s co-founder and Chief Scientific Officer, Lawrence Lamb, Ph.D. “We believe that the unique properties of these immune cells and their clinical correlation with improved patient survival make them a potentially powerful cellular therapy against cancer,” said William Ho, co-founder and Chief Executive Officer of IN8bio. “The research that Dr. Lamb presented underscores the potential utility of gamma-delta T cells and serves as the foundation for our two clinical programs. INB-200, which is in Phase 1 development for newly diagnosed glioblastoma, and INB-100, which is in Phase 1 development for leukemia patients undergoing hematopoietic stem cell transplantation.” Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. These cells can functionally bridge the innate and adaptive immune systems, both contributing to direct tumor killing as well as antigen presentation to recruit a broad population of cells to drive deeper immune responses. Research has demonstrated that both higher levels of gamma-delta T cells and the presence of infiltrating gamma-delta T cells are correlated with better survival outcomes. Chemotherapy, a mainstay of solid tumor treatment, depletes and damages gamma-delta T cells, limiting their ability to seek and kill tumor cells. Dr. Lamb’s ESMO presentation, which explains the scientific basis for IN8bio’s DRI platform, describes how genetic modifications can be leveraged to protect gamma-delta T cells from chemotherapy-induced damage. This allows gamma-delta T cells to be dosed concurrently with chemotherapy to attack the tumor when it is most vulnerable. IN8bio is currently conducting a Phase 1 clinical trial of INB-200 as an adjuvant to standard of care during maintenance chemotherapy treatment in newly diagnosed glioblastoma. Topline Phase 1 results are expected to be presented at a major medical conference in the second half of 2021. About IN8bio IN8bio is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous or genetically modified gamma-delta T cells. IN8bio’s technology incorporates DRI, which has been shown in preclinical studies to function in combination with therapeutic levels of chemotherapy. IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. For more information about the Company and its programs, visit www.IN8bio.com. Forward Looking StatementsCertain statements herein concerning the Company’s future expectations, plans and prospects, including without limitation, the Company’s current expectations regarding the advancement of its product candidates through clinical trials and the achievement of clinical milestones, constitute forward-looking statements. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” the negative of these and other similar expressions are intended to identify such forward looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond the Company’s control. Consequently, actual future results may differ materially from the anticipated results expressed in such statements. Specific risks which could cause actual results to differ materially from the Company’s current expectations include: scientific, regulatory and technical developments; failure to demonstrate safety, tolerability and efficacy; final and quality controlled verification of data and the related analyses; expense and uncertainty of obtaining regulatory approval, including from the U.S. Food and Drug Administration; and the Company’s reliance on third parties, including licensors and clinical research organizations. Do not place undue reliance on any forward-looking statements included herein, which speak only as of the date hereof and which the Company is under no obligation to update or revise as a result of any event, circumstances or otherwise, unless required by applicable law. Company Contact:IN8bio, Inc.Kate Rochlin, Ph.D.+1 646.600.6GDT (6438)info@IN8bio.com Investors:Solebury TroutJulia Balanova+ 1 646.378.2936jbalanova@soleburytrout.com Media:Burns McClellan, Inc.Ryo Imai / Robert Flamm, Ph.D.+1 212.213.0006 - ext. 315 / 364rimai@burnsmc.com / rflamm@burnsmc.com

  • CoreSite Empowers Enterprises to Innovate with Leading Local Cloud as a Service Solution – VMware Cloud on Dell EMC

    CoreSite Realty Corporation (NYSE:COR) (the "Company"), a premier provider of secure, reliable, high-performance data center, cloud access and interconnection solutions across the U.S., and a VMware Technology Alliance Partner, today announced the availability of VMware® Cloud™ on Dell EMC®. This fully managed infrastructure as a service offering is available across CoreSite’s national platform of enterprise-class, cloud-enabled data center campuses. CoreSite and VMware have created a Center of Excellence, technical validation proof of concept (PoC) lab, to accelerate innovation and cost savings for enterprises challenged with today’s escalating capital IT expenses, while also enabling emerging requirements of low-latency applications and data sovereignty management. The solution also future proofs enterprises for tomorrow’s AI, machine-learning, IoT and 5G use cases.

  • Canacol Energy Ltd. Provides February Gas Sales and Drilling Update

    CALGARY, Alberta, March 02, 2021 (GLOBE NEWSWIRE) -- Canacol Energy Ltd. ("Canacol" or the "Corporation") (TSX:CNE; OTCQX:CNNEF; BVC:CNEC) is pleased to provide the following information concerning its February 2021 natural gas sales and drilling program. Gas Sales Averaged 187 MMscfpd for February 2021 Realized contractual natural gas sales (which are gas produced, delivered, and paid for) were 187 million standard cubic feet per day (“MMscfpd”) for February 2021, a 6% increase from average gas sales of 177 MMscfpd for the month of January 2021. Flauta 1 and Oboe 2 The Flauta 1 exploration well which completed drilling in February 2021 did not encounter commercial gas and has been plugged and abandoned. The Oboe 2 development well has been completed as a successful gas producer and is being tied into the Jobo gas processing facility. The rigs are currently being mobilized to drill the Cañahuate 4 development well and the Milano 1 exploration well, both of which are anticipated to spud the second week of March 2021. Each will take approximately 5 weeks to drill and test. About Canacol Canacol is a natural gas exploration and production company with operations focused in Colombia. The Corporation's common stock trades on the Toronto Stock Exchange, the OTCQX in the United States of America, and the Colombia Stock Exchange under ticker symbol CNE, CNNEF, and CNE.C, respectively. This press release contains certain forward-looking statements within the meaning of applicable securities law. Forward-looking statements are frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur, including without limitation statements relating to estimated production rates from the Corporation's properties and intended work programs and associated timelines. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Corporation cannot assure that actual results will be consistent with these forward-looking statements. They are made as of the date hereof and are subject to change and the Corporation assumes no obligation to revise or update them to reflect new circumstances, except as required by law. Prospective investors should not place undue reliance on forward looking statements. These factors include the inherent risks involved in the exploration for and development of crude oil and natural gas properties, the uncertainties involved in interpreting drilling results and other geological and geophysical data, fluctuating energy prices, the possibility of cost overruns or unanticipated costs or delays and other uncertainties associated with the oil and gas industry. Other risk factors could include risks associated with negotiating with foreign governments as well as country risk associated with conducting international activities, and other factors, many of which are beyond the control of the Corporation. Realized contractual gas sales is defined as gas produced and sold plus gas revenues received from nominated take or pay contracts. CONTACT: For more information please contact: Investor Relations South America: +571.621.1747 IR-SA@canacolenergy.com Global: +1.403.561.1648 IR-GLOBAL@canacolenergy.com http://www.canacolenergy.com

  • Baudax Bio to Present at the H.C. Wainwright Global Life Sciences Conference

    MALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, President and Chief Executive Officer, will give a corporate presentation at the H.C. Wainwright Global Life Sciences Conference, being held virtually March 9-10, 2021. The presentation will be made available for on-demand listening beginning Tuesday, March 9th at 7:00 a.m. Eastern Time and may be accessed on the “Presentations” page within the investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. The recording will be made available for a period of 30 days following the event. About Baudax Bio Baudax Bio is a pharmaceutical company focused on therapeutics for acute care settings. The launch of Baudax Bio’s first commercial product ANJESO® began in June 2020 following its approval by the U.S. Food and Drug Administration in February 2020. ANJESO is a once daily IV NSAID with preferential Cox-2 activity, which has successfully completed three Phase III clinical trials, including two pivotal efficacy trials, a large double-blind Phase III safety trial and other studies for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs which is currently in preclinical studies, and intranasal dexmedetomidine which is being developed for possible uses in pain or sedation. For more information please visit www.baudaxbio.com. CONTACT: Investor Relations Contact:Argot PartnersSam Martin / Claudia Styslinger(212) 600-1902baudaxbio@argotpartners.com Baudax Bio, Inc.Ryan D. Lake(484) 395-2436rlake@baudaxbio.com Media Contact:Argot PartnersDavid Rosen(212) 600-1902david.rosen@argotpartners.com

  • Better Buy: Alibaba vs. Facebook

    Both tech giants face fierce regulatory headwinds, but one of these stocks is clearly a stronger long-term investment.

  • Athira Pharma to Present at H.C. Wainwright & Co. Global Life Sciences Conference

    BOTHELL, Wash., March 02, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Leen Kawas, Ph.D., President and Chief Executive Officer, will present a corporate overview during the H.C. Wainwright & Co. Global Life Sciences Conference. A pre-recorded presentation will be available for on-demand viewing beginning at 7:00 am ET on Tuesday, March 9, 2021. A webcast of the presentation will also be available on the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations. An archived replay of the webcast will be available for approximately 90 days following the event. About Athira Pharma, Inc.Athira, headquartered in Seattle, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. We aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer’s and Parkinson’s dementia. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram. Investor & Media Contact:Julie RathbunAthira PharmaJulie.rathbun@athira.com206-769-9219

  • GasLog Partners LP Announces Availability of its Annual Report on Form 20-F for the Year Ended December 31, 2020

    Piraeus, Greece, March 02, 2021 (GLOBE NEWSWIRE) -- GasLog Partners LP (“GasLog Partners” or the “Partnership”) (NYSE: GLOP) announced today that its Annual Report on Form 20-F for the fiscal year ended December 31, 2020 (the “Annual Report”) has been filed with the U.S. Securities and Exchange Commission and can be accessed on the Partnership’s website, http://www.gaslogmlp.com, in the “Investor Relations” section under “SEC Filings”. Unitholders may also request a hard copy of the Annual Report, which includes the Partnership’s complete 2020 audited financial statements, free of charge by contacting: Email: ir@gaslogmlp.com Phone: +1-212-223-0643 About GasLog Partners GasLog Partners is a growth-oriented owner, operator and acquirer of LNG carriers. The Partnership’s fleet consists of 15 LNG carriers with an average carrying capacity of approximately 158,000 cbm. GasLog Partners is a publicly traded master limited partnership (NYSE: GLOP) but has elected to be treated as a C corporation for U.S. income tax purposes and therefore its investors receive an Internal Revenue Service Form 1099 with respect to any distributions declared and received. The Partnership’s principal executive offices are located at 69 Akti Miaouli, 18537, Piraeus, Greece. Visit GasLog Partners’ website at http://www.gaslogmlp.com. Contacts:Joseph NelsonHead of Investor RelationsPhone: +1-212-223-0643 Email: ir@gaslogmlp.com

  • Hamilton Lane Closes Latest Strategic Opportunities Fund Series on Nearly $900M

    Sixth Series Designed to Target Private Credit Investments around the WorldBALA CYNWYD, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Leading private markets investment management firm Hamilton Lane (NASDAQ: HLNE) today announced the final closing of Hamilton Lane Strategic Opportunities Fund VI (“the Fund”). The Fund represents nearly $900 million in commitments from a wide range of global LPs. The Fund is focused on making credit-oriented investments striving for consistent cash yield, shorter duration and attractive risk-adjusted returns. Consistent with previous vintage vehicles, the Fund is comprised of a diverse set of institutions, including returning as well as new investors from Asia, the Middle East, Europe and North and South America. Drew Schardt, Head of Direct Credit at Hamilton Lane, commented: “The private credit landscape continues to evolve, marked by growing LP interest driven generally by the opportunity for risk mitigation, yield and return characteristics offered within the context of a broader private markets portfolio.” “This latest close is a continuation of our proven strategy and platform, and of our ability to bring to bear more than two decades of experience, differentiated deal flow and strong relationships to consistently access unique private credit-oriented opportunities on a global level,” he said. Jackie Rantanen, Head of Product Management at Hamilton Lane, said: “We’re thankful to our strong global client base for supporting what is our sixth successful fundraise for the Strategic Opportunities Series. We intentionally structure this Series as a unique and appealing solution for investors seeking a high level of flexibility and optionality, while benefiting from Hamilton Lane’s extensive global platform and opportunity set.” Hamilton Lane has long been an active investor in targeted strategies, including credit-oriented direct investments and co-investments. While this vehicle represents the sixth of its kind, it is an extension of Hamilton Lane’s broader credit platform, which the firm has been building for over 20 years and which represents more than $40 billion in assets under management and supervision as of September 30, 2020. About Hamilton LaneHamilton Lane (NASDAQ: HLNE) is a leading private markets investment management firm providing innovative solutions to sophisticated investors around the world. Dedicated exclusively to private markets investing for 29 years, the firm currently employs more than 440 professionals operating in offices throughout North America, Europe, Asia Pacific and the Middle East. Hamilton Lane has approximately $657 billion in assets under management and supervision, composed of approximately $76 billion in discretionary assets and approximately $581 billion in advisory assets, as of December 31, 2020. Hamilton Lane specializes in building flexible investment programs that provide clients access to the full spectrum of private markets strategies, sectors and geographies. For more information, please visit www.hamiltonlane.com or follow Hamilton Lane on Twitter: @hamilton_lane. Forward-Looking Statements Some of the statements in this release may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Words such as “will,” “expect,” “believe,” “estimate,” “continue,” “anticipate,” “intend,” “plan” and similar expressions are intended to identify these forward-looking statements. Forward-looking statements discuss management’s current expectations and projections relating to our financial position, results of operations, plans, objectives, future performance and business. All forward-looking statements are subject to known and unknown risks, uncertainties and other important factors that may cause actual results to be materially different, including risks relating to: our ability to manage growth, fund performance, risk, changes in our regulatory environment and tax status; market conditions generally; our ability to access suitable investment opportunities for our clients; our ability to maintain our fee structure; our ability to attract and retain key employees; our ability to manage our obligations under our debt agreements; defaults by clients and third-party investors on their obligations to fund commitments; our ability to comply with investment guidelines set by our clients; our ability to consummate planned acquisitions and successfully integrate the acquired businesses with ours; our ability to manage risks associated with pursuing new lines of business; our ability to manage the effects of events outside of our control; and our ability to receive distributions from Hamilton Lane Advisors, L.L.C. to fund our payment of dividends, taxes and other expenses. The foregoing list of factors is not exhaustive. For more information regarding these risks and uncertainties as well as additional risks that we face, you should refer to the “Risk Factors” detailed in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended March 31, 2020 and in our subsequent reports filed from time to time with the Securities and Exchange Commission. The forward-looking statements included in this release are made only as of the date hereof. We undertake no obligation to update or revise any forward-looking statement as a result of new information or future events, except as otherwise required by law. Media ContactKate McGannkmcgann@hamiltonlane.com+1 240 888 4078 Investor ContactJohn Ohjoh@hamiltonlane.com +1 610 617 6026